Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Climate Change
---FY 2023 Appropriations
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---International Consistency of Regulation for Gene Edited Products
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Funding for the USDA
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX

Genetically Engineered (GE) Animals
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Genetically Engineered (GE) Plants
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Climate Issues & impact on the agriculture, food, and forestry sectors
---EPA Regulatory Approach to Gene Editing
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)
---FDA Proposed guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products

USDA/APHIS Agricultural Biotechnology Regulations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---The Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule under the Plant Protection Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Food & Drug Administration (FDA), Environmental Protection Agency (EPA), Natl Security Council (NSC), State - Dept of (DOS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---Implementation of Consolidated Appropriations Act for FY 2021
------Sec 778: GE Salmon language
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.5376: Build Back Better Act of 2021
---S.3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Build Back Better Act (Discussion Draft Senate)
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2023 Appropriations
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2023 Appropriations
---H.R.4521: America COMPETES Act of 2022
---H.R.5376: Build Back Better Act of 2021
---S.1260: United States Innovation and Competition Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Reauthorization of PAHPA

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---H.R.5376: Build Back Better Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of Consolidated Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels

Funding for Biorefineries
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---Climate Issues & impact on the agriculture, food, and forestry sectors

Funding for FDA
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---H.R.7667: The Food and Drug Amendments of 2022
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2023 Appropriations
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for National Institutes of Health
---FY 2023 Appropriations
---H.R.623: Gabriella Miller Kids First Research Act 2.0
---H.R.5585: Advanced Research Projects Agency for Health (ARPA-H) Act

Funding for Renewable Chemicals/Bio-based Products
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2023 Appropriations
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2023 Appropriations

Funding for the USDA
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office, Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill

Renewable Chemicals/Bio-based Products (Non-Funding)
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---S.1298: Clean Energy for America Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Investment Tax Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021
---Proposed FTC/DOJ Merger Guidelines

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights
---NIST Proposed Rulemaking on Bayh-Dole

Coronavirus (COVID-19) Pandemic
---Restrictions on Intellectual Property Rights
---TRIPS Waiver
---Coronavirus Supplemental Appropriations

Data Privacy Issues
---S.2499: Setting an American Framework to Ensure Data Access, Transparency, and Accountability (SAFE DATA) Act
---US-EU Privacy Shield

Drug Patenting
---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications
---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act
---H.R.5902: CLEAR Patents Act of 2021
---S.2774: Pride in Patent Ownership Act
---S.2891: Restoring the America Invents Act
---Restrictions on Intellectual Property Rights

Intellectual Property Enforcement
---TRIPS Waiver

Inter Partes Review
---H.R.5874: Restoring America's Leadership in Innovation Act
---H.R.5902: CLEAR Patents Act of 2021
---S.2774: Pride in Patent Ownership Act
---S.2891: Restoring the America Invents Act
---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft)

Patent Reform
---S.1260: United States Innovation and Competition Act of 2021
------Ownership and Assignments of Patents
---S.4417: Patent Trial and Appeal Board Reform Act of 2022
---S.4430: Interagency Patent Coordination and Improvement Act of 2022
---Patent Litigation Reform

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), White House Office, Commerce - Dept of (DOC), Federal Trade Commission (FTC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---FY 2023 Appropriations
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---H.R.5376: Build Back Better Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of Consolidated Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)
---FY 2023 Appropriations
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---Implementation of Consolidated Appropriations Act for FY 2021
------Sec 778: GE Salmon language
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---FY 2023 Appropriations
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---H.R.2820/S.1251: The Growing Climate Solutions Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---FY 2023 Energy and Water Development and Related Agencies funding bill
---H.R.5376: Build Back Better Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of Consolidated Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)
---FY 2023 Appropriations
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

21st Century Cures Act 2.0
---H.R.6000: Cures 2.0 Act

340B Drug Discount Program
---Program Implementation & Oversight

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of 21st Century Cures Act of 2016
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Reauthorization of PAHPA
---Tropical Disease Priority Review (PRV) Program
---White House National Biodefense Strategy

Biosimilars
---H.R.7035: Biologics Market Transparency Act
---H.R.7047: A bill to Amend title III of PHSA re: determination re: biosimilar application elements
---Biosimilar Copay
---BSUFA Negotiations
---Interchangeability and Pharmacy Substitution
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---Reimbursement

Coronavirus (COVID-19) Pandemic
---H.R.834: Pandemics Require Evaluating, Planning, And Responding Effectively (PREPARE) Act
---S.2327: Seniors Prescription Drug Relief Act
---S.3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Defense Production Act (DPA)
---Drug Supply Chain Management
---Healthcare Disparities
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of Families First Coronavirus Response Act of 2020
---Medicare Reimbursement Policies
---Monoclonal Antibody Coverage and Utilization
---Patient Cost-Sharing and Smoothing
---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement
---R&D Funding for Medical Countermeasures
---Temporarily Refundable R&D Credit
---Restrictions on Intellectual Property Rights
---Senate HELP Pandemic Preparedness White Paper
---Small Business Loans
---Supply Chain Issues
---TRIPS IP Waiver

Climate Change
---FY 2023 Appropriations

Data Privacy
---H.R.8152: American Data Privacy and Protection Act

Diagnostics and Personalized Medicine Regulation and Oversight
---H.R.4128/S.2209: VALID Act

Diversity & Inclusion
---H.R.729: Strength in Diversity Act of 2021
---H.R.3085: Equity in Neuroscience and Alzheimer's Clinical Trials (ENACT) Act of 2021
---H.R.5030: Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act
---H.R.6584: Diverse and Equitable Participation in Clinical Trials (DEPICT) Act
---H.R.7667: The Food and Drug Amendments of 2022
---S.3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Clinical Trial Diversity

Drug Evaluation and Review
---H.R.3927/S.2082: Manufacturing API, Drugs, and Excipients (MADE) in America Act
---H.R.4472: Better Empowerment Now To Enhance Framework and Improve Treatments (BENEFIT) Act
---H.R.4511: FDA Advancing Collection of Transformative Science (FACTS) Act
---H.R.6963: Accelerated Approval Integrity Act
---H.R.6972/S.4215: Give Kids a Chance Act of 2022
---H.R.6996: Accelerating Approval for Patients Act
---H.R.7008: The Pre-Approval Information Exchange Act
---H.R.7032/S.4338: Increasing Transparency in Generic Drug Applications Act
---H.R.7667: The Food and Drug Amendments of 2022
---S.1644 Promising Pathway Act
---S.1645: Accelerated Drug Approval for Prescription Therapies ADAPT Act
---S.4185: Retaining Access and Restoring Exclusivity (RARE) Act
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---S.4351: Enhanced Access to Affordable Medicines Act of 2022
---COVID-19 Lessons Learned
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---FDA Review of CBD-based Drugs
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Patient-Focused Drug Development
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Priority Review Voucher Programs
---Reforms to the Accelerated Approval Pathway
---Regulatory Reform & Modernization
---Use of Real-World Evidence

Drug Importation
---S.920: A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022

Drug Manufacturing, Quality & Distribution
---H.R.1959: Preserving Patient Access to Compounded Medications Act of 2019
---H.R.3927/S.2082: Manufacturing API, Drugs, and Excipients (MADE) in America Act
---H.R.6988: Drug Manufacturing Innovation Act
---H.R.7006: Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and overseeing Needed Supplies (INSPECTIONS) Act
---H.R.7767: A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment.
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Counterfeiting
---Drug Shortages
---Executive Order on Buy American
---Pharmacy Compounding & Oversight
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications
---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.4418: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act
---H.R.5376: Build Back Better Act of 2021
---H.R.7667: The Food and Drug Amendments of 2022
---S.1388: Prescription Pricing for the People Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---S.2327: Seniors Prescription Drug Relief Act
---S.4293: Pharmacy Benefit Manager Transparency Act of 2022
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Build Back Better Act (Discussion Draft Senate)
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Implementation of Consolidated Appropriations Act for FY 2021
---National Coverage Determination

Foreign Drug Data Protection Laws
---Regulatory Harmonization

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2023 Appropriations
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2023 Appropriations
---H.R.4521: America COMPETES Act of 2022
---H.R.5376: Build Back Better Act of 2021
---S.1260: United States Innovation and Competition Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Reauthorization of PAHPA

Funding for FDA
---FY 2023 Appropriations
---FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies funding bill
---H.R.7667: The Food and Drug Amendments of 2022
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2023 Appropriations
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for National Institutes of Health
---FY 2023 Appropriations
---H.R.623: Gabriella Miller Kids First Research Act 2.0
---H.R.5585: Advanced Research Projects Agency for Health (ARPA-H) Act

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2023 Appropriations
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2023 Appropriations

Generic Drug Entry
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2853: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2021
---H.R.6973/S.4351: Enhanced Access to Affordable Medicines Act
---H.R.7032/S.4338: Increasing Transparency in Generic Drug Applications Act
---H.R.7667: The Food and Drug Amendments of 2022
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.5125: Strengthening Innovation in Medicare and Medicaid Act
---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019
---S.4293: Pharmacy Benefit Manager Transparency Act of 2022
---Alternative Payment Arrangements for Gene Therapies
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Implementation of Consolidated Appropriations Act for FY 2021
---Pricing and Rebates

Opioid Crisis
---Coverage and Reimbursement
---FDA Reforms
---Implementation of the SUPPORT for Patients and Communities Act of 2018

Orphan Drug Issues
---H.R.1629: Fairness in Orphan Drug Exclusivity Act
---H.R.5376: Build Back Better Act of 2021
---H.R.5566 Finding Orphan-Disease Remedies With Antifungal Research and Development (FORWARD) Act
---S.4184 Retaining Access and Restoring Exclusivity (RARE) Act
---Build Back Better Act (Discussion Draft Senate)
---Orphan Drug Tax Credit

Precision Medicine Initiative

Rare Pediatric Disease Priority Review
---H.R.1730: Speeding Therapy Access Today (STAT) Act
---H.R.6888/S.4071: Helping Experts Accelerate Rare Treatments (HEART) Act
---H.R.6972/S.4215: Give Kids a Chance Act of 2022
---Implementation of Consolidated Appropriations Act for FY 2021
---Rare Disease Pilot Program

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.5376: Build Back Better Act of 2021
---S.2327: Seniors Prescription Drug Relief Act
---S.2416: New Opportunities for Value that Extend Lives (NOVEL) Act of 2021
---Administration Rebate Rule
---Build Back Better Act (Discussion Draft Senate)
---CMMI Authority
---Implementation of Consolidated Appropriations Act for FY 2021
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations

Vaccines and Infectious Diseases
---FY 2023 Appropriations
---H.R.951/H.R.959/S.345/S.346: Maternal Vaccinations Act of 2021
---H.R.1978/S.912: Protecting Seniors through Immunizations Act of 2021
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347/S.2691: Strengthening the Vaccines for Children Program Act of 2021
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---S.4509: Vaccine and Coverage Certainty (VACC) Act
---Adult Immunization
---Implementation of Consolidated Appropriations Act for FY 2021
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---Recovery of Routine Immunizations
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety

Vaccine Injury Compensation Program
---FY 2023 Appropriations
---H.R.3656: Vaccine Access Improvement Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of 21st Century Cures Act of 2016
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Reauthorization of PAHPA
---Tropical Disease Priority Review (PRV) Program
---White House National Biodefense Strategy

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2023 Appropriations
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2023 Appropriations
---H.R.4521: America COMPETES Act of 2022
---H.R.5376: Build Back Better Act of 2021
---S.1260: United States Innovation and Competition Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of Consolidated Appropriations Act for FY 2021
---Reauthorization of PAHPA

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of 21st Century Cures Act of 2016
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Reauthorization of PAHPA
---Tropical Disease Priority Review (PRV) Program
---White House National Biodefense Strategy

Coronavirus (COVID-19) Pandemic
---H.R.550: Immunization Information Systems
---Implementation of Consolidated Appropriations Act for FY 2021
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2023 Appropriations
---H.R.3932/S.2076: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)
---H.R.4127: DISARM Act
---Implementation of Consolidated Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2023 Appropriations
---H.R.4521: America COMPETES Act of 2022
---H.R.5376: Build Back Better Act of 2021
---S.1260: United States Innovation and Competition Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Reauthorization of PAHPA

Funding for National Institutes of Health
---FY 2023 Appropriations
---H.R.623: Gabriella Miller Kids First Research Act 2.0
---H.R.5585: Advanced Research Projects Agency for Health (ARPA-H) Act

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2023 Appropriations
---Funding for 2022-2023 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of Consolidated Appropriations Act for FY 2021
---Implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

21st Century Cures Act 2.0
---H.R.6000: Cures 2.0 Act

340B Drug Discount Program
---Program Implementation & Oversight

Coronavirus (COVID-19) Pandemic
---H.R.550: Immunization Information Systems
---S.2327: Seniors Prescription Drug Relief Act
---COVID-19 Pricing-Related Provisions
---Implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Patient Cost-Sharing and Smoothing

Data Privacy
---H.R.8152: American Data Privacy and Protection Act

Drug Pricing
---FY 2023 Appropriations
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2071: Medicare Prescription Drug Price Negotiation Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.4811: Medicare Negotiation and Competitive Licensing Act
---H.R.5125: Strengthening Innovation in Medicare and Medicaid Act
---H.R.5376: Build Back Better Act of 2021
---H.R.7667: The Food and Drug Amendments of 2022
---S.1388: Prescription Pricing for the People Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---S.2327: Seniors Prescription Drug Relief Act
---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022
---Build Back Better Act (Discussion Draft Senate)
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Implementation of Consolidated Appropriations Act for FY 2021
---National Coverage Determination

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.5125: Strengthening Innovation in Medicare and Medicaid Act
---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019
---S.4293: Pharmacy Benefit Manager Transparency Act of 2022
---Alternative Payment Arrangements for Gene Therapies
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Implementation of Consolidated Appropriations Act for FY 2021
---Pricing and Rebates

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.2139/S.908: Medicare Drug Price Negotiation Act
---H.R.2148/S.909: Prescription Drug Price Relief Act
---H.R.5376: Build Back Better Act of 2021
---S.2327: Seniors Prescription Drug Relief Act
---S.2416: New Opportunities for Value that Extend Lives (NOVEL) Act of 2021
---S.3018: Improving Seniors Timely Access to Care Act of 2021
---Administration Rebate Rule
---Build Back Better Act (Discussion Draft Senate)
---CMMI Authority
---Implementation of Consolidated Appropriations Act for FY 2021
---Medicare 2023 IPPS Proposed Rule Comment Letter
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations

Vaccines and Infectious Diseases
---FY 2023 Appropriations
---H.R.1978/S.912: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.4127: DISARM Act
---Separate Payment Mechanism for Innovative Antimicrobials Products

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---H.R.1304/S.749: American Innovation and Jobs Act
---H.R.5376: Build Back Better Act of 2021
---H.R.7555: A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7556: A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research
---Build Back Better Act (Discussion Draft Senate)
--- H.R.3623/S.2529: Innovation and Growth Now by Investing in Tomorrow's Enterprises (IGNITE) American Innovation Act
---Reform of New Operating Loss Rules

Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---SEC Small Business Forum

Coronavirus (COVID-19) Pandemic
---Small Business Loans

Small Business Innovation Research (SBIR) Program
---H.R.4521: America COMPETES Act of 2022
---S.1260: United States Innovation and Competition Act of 2021
---Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC), Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Capital Formation Incentives
---H.R.1304/S.749: American Innovation and Jobs Act
---H.R.5376: Build Back Better Act of 2021
---H.R.7555: A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7556: A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---Build Back Better Act (Discussion Draft Senate)
---Reform of New Operating Loss Rules

Coronavirus (COVID-19) Pandemic
---Temporarily Refundable R&D Credit

Orphan Drug Issues
---S.4184 Retaining Access and Restoring Exclusivity (RARE) Act
---Tax Credit

Qualified Small Business Stock (QSBS)
---H.R.5376: Build Back Better Act of 2021
---Build Back Better Act (Discussion Draft Senate)

Renewable Chemicals/Bio-based Products (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---H.R.1304/S.749: American Innovation and Jobs Act
---H.R.5376: Build Back Better Act of 2021
------R&D Amortization
---H.R.7767: A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment.
---H.R.1304/S.749: American Innovation and R&D Competitiveness Act of 2021
---Build Back Better Act (Discussion Draft Senate)
---Expensing of R&D Expenditures
---R&D Payroll Credit

Vaccine Injury Compensation Program
---FY 2023 Appropriations
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Digital Trade
---EU Digital Strategy

Drug Pricing
---Reference Pricing in Drug Reimbursement

Foreign Agricultural Biotechnology Laws and Regulations
---FY 2023 Commerce, Justice, Science, and Related Agencies funding bill
---Asynchronous Approval
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---International Consistency of Regulation for Gene Edited Products
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Genetically Engineered (GE) Animals
---International Consistency of Regulation for Gene Edited Products

Genetically Engineered (GE) Plants
---International Consistency of Regulation for Gene Edited Products

Intellectual Property International Enforcement
---China
---TRIPS Waiver

US-China Trade Agreement
---Ag-Biotech Provisions

US-UK Trade Agreement
---Ag-Biotech Provisions

World Trade Organization
---TRIPS Waiver

World Health Organization (WHO)
---TRIPS Waiver

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), White House Office, Natl Security Council (NSC), Patent & Trademark Office (PTO), State - Dept of (DOS), Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes